Brahmi (Bacopa monnieri)

About

What it is and where it shows up.

Brahmi (Bacopa monnieri) is a perennial creeping herb native to India and used for centuries in Ayurvedic medicine as a cognitive enhancer, anxiolytic, and memory-improving botanical. Its pharmacological activity is attributed primarily to triterpenoid saponins (bacosides) and alkaloids; it is consumed as a nutraceutical, health supplement, or herbal food preparation.

Safety summary

The regulatory and scientific consensus.

Brahmi has a high therapeutic index and is generally well-tolerated in healthy adults; the most common adverse effects are gastrointestinal, including nausea, increased stool frequency, and abdominal cramps. A NOAEL of 500 mg/kg body weight was established in rat studies, and no hepatotoxicity has been documented in clinical use; however, no formal human ADI has been established. Safety data are insufficient for pregnant and breastfeeding women, and interactions with thyroid medications and contraindications in hyperthyroidism require consideration.

Regulatory landscape

What food-safety regulators have decided.

Jurisdiction	Status	Note
FDA (Food and Drug Administration) (United States)	Restricted	Regulated as a dietary supplement under DSHEA (1994); not approved for any medical purpose. In 2019, FDA issued warning letters to manufacturers making therapeutic claims about Bacopa monnieri products. No GRAS status has been conferred for use as a conventional food ingredient.source
FSSAI (Food Safety and Standards Authority of India) (India)	Approved	Permitted as a botanical plant ingredient in health supplements and nutraceuticals under FSS (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2016 (amended September 2021, FBOs to comply by April 2022). Specific health-benefit claims require prior FSSAI approval. Products intended for children aged 2–5 years may only be given under medical advice.source
EFSA (European Food Safety Authority) (European Union)	Under_review	No E-number or EU food-additive authorisation. Sold as a botanical food supplement; EFSA has not completed a formal positive safety opinion. May require Novel Food authorisation under Regulation (EU) 2015/2283 if pre-1997 history of significant EU consumption cannot be demonstrated. Member-state rules on botanical supplements vary.source

Who should approach with care

Whose guidance would steer them away.

Pregnancy — Insufficient clinical safety data exist for pregnant women; further research is needed to determine safe dosages, and use should only occur under medical supervision.

Lactation — Safety during breastfeeding has not been established in controlled studies; caution is advised until adequate evidence is available.

Thyroid Disease — Brahmi is contraindicated in hyperthyroidism and may interact with thyroid medications, potentially altering thyroid hormone levels.

Infants — FSSAI Nutraceuticals Regulations stipulate that products intended for children aged 2–5 years may only be administered under medical advice from a physician or certified dietician.

Epilepsy — Brahmi has sedative and neuroactive properties that may interact with anti-epileptic drugs; medical supervision is advised for patients on anti-seizure therapy.

Research citations

The sources behind this verdict.

1PubMed. Bacopa monnieri: Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability, 2025. pmc.ncbi.nlm.nih.gov
2other. Bacopa monnieri – LiverTox (NCBI Bookshelf / NIH NIDDK), 2024. ncbi.nlm.nih.gov
3PubMed. Bacopa monnieri (StatPearls, NCBI Bookshelf), 2023. ncbi.nlm.nih.gov
4PubMed. Mechanisms, Efficacy, and Safety of Bacopa monnieri (Brahmi) for Cognitive and Brain Enhancement, 2015. pubmed.ncbi.nlm.nih.gov
5PubMed. Safety evaluation of a standardized phytochemical composition extracted from Bacopa monnieri in Sprague-Dawley rats, 2007. pubmed.ncbi.nlm.nih.gov

Independently researched5 citations